Perona-Moratalla, A.B.; Carrión, B.; Villar Gómez de las Heras, K.; Arias-Salazar, L.; Yélamos-Sanz, B.; Segura, T.; Serrano-Heras, G.
Dual Inhibition of HIF-1α and HIF-2α as a Promising Treatment for VHL-Associated Hemangioblastomas: A Pilot Study Using Patient-Derived Primary Cell Cultures. Biomedicines 2025, 13, 1234.
https://doi.org/10.3390/biomedicines13051234
AMA Style
Perona-Moratalla AB, Carrión B, Villar Gómez de las Heras K, Arias-Salazar L, Yélamos-Sanz B, Segura T, Serrano-Heras G.
Dual Inhibition of HIF-1α and HIF-2α as a Promising Treatment for VHL-Associated Hemangioblastomas: A Pilot Study Using Patient-Derived Primary Cell Cultures. Biomedicines. 2025; 13(5):1234.
https://doi.org/10.3390/biomedicines13051234
Chicago/Turabian Style
Perona-Moratalla, Ana B., Blanca Carrión, Karina Villar Gómez de las Heras, Lourdes Arias-Salazar, Blanca Yélamos-Sanz, Tomás Segura, and Gemma Serrano-Heras.
2025. "Dual Inhibition of HIF-1α and HIF-2α as a Promising Treatment for VHL-Associated Hemangioblastomas: A Pilot Study Using Patient-Derived Primary Cell Cultures" Biomedicines 13, no. 5: 1234.
https://doi.org/10.3390/biomedicines13051234
APA Style
Perona-Moratalla, A. B., Carrión, B., Villar Gómez de las Heras, K., Arias-Salazar, L., Yélamos-Sanz, B., Segura, T., & Serrano-Heras, G.
(2025). Dual Inhibition of HIF-1α and HIF-2α as a Promising Treatment for VHL-Associated Hemangioblastomas: A Pilot Study Using Patient-Derived Primary Cell Cultures. Biomedicines, 13(5), 1234.
https://doi.org/10.3390/biomedicines13051234
